High Expression of the “A Disintegrin And Metalloprotease” 19 (ADAM19), a Sheddase for TNF-α in the Mucosa of Patients with Inflammatory Bowel Diseases

ADAM19 autolysis is activated by LPS and promotes non-classical secretion of cysteine-rich protein 2

(2010) Chiaki Tanabe et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Enhand secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina ropria monouclear cells from patients with ulcretive cilitis and Crohn's disease

(2010) H.-C. REINECKER et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections

(2009) S. SCHNEEWEISS et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

(2009) Javier P Gisbert et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

ADAM19/Adamalysin 19 Structure, Function, and Role as a Putative Target in Tumors and Inflammatory Diseases

(2009) Bin Qi et al.   CURRENT PHARMACEUTICAL DESIGN

Biological Therapies for Inflammatory Bowel Diseases

(2009) Paul Rutgeerts et al.   GASTROENTEROLOGY

Inflammatory Bowel Disease

(2009) Clara Abraham et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expression of ADAMs (“a disintegrin and metalloprotease”) in the human lung

(2009) Antoon Dijkstra et al.   VIRCHOWS ARCHIV

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

(2008) H Fidder et al.   GUT